Genelux Corp (GNLX)
Health Care · Oncolytic viral immunotherapy / biopharmaceutical · NASDAQ
Genelux is a late clinical-stage biopharmaceutical company developing oncolytic vaccinia virus immunotherapies designed to selectively kill tumor cells and trigger personalized anti-tumor immune responses.
What Genelux Corp does
Genelux is a late clinical-stage biopharmaceutical company focused on developing oncolytic viral immunotherapies for aggressive and difficult-to-treat cancers. The company's lead candidate, Olvi-Vec, is a proprietary modified vaccinia virus designed to selectively kill tumor cells and induce patient-specific immune responses against tumor neoantigens. Olvi-Vec is being evaluated in three clinical trials: a Phase 3 registrational trial for platinum-resistant ovarian cancer, a Phase 2 trial for recurrent non-small cell lung cancer, and a Phase 1b/2 trial in China for recurrent small cell lung cancer. Genelux operates its own cGMP manufacturing facility in San Diego, California and has licensed development rights in China to partner Newsoara.
Themes: oncolytic viruses / oncolytic immunotherapy, cancer immunotherapy, platinum-resistant ovarian cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), personalized / neoantigen-based immunotherapy
Fundamentals
- Price$2.73 as of 2026-08-26 close
- Market cap$124M as of 2026-08-26
- 1-year return-28.0% 2025-08-26 close $3.79 → 2026-08-26 close $2.73
- P/En/a negative earnings
- Net margin-115587.5% as of 2026-08-27
- ROE-174.6% as of 2026-08-27
- Debt / equity0.00 as of 2026-08-27
- Revenue growth (YoY)-91.0% as of 2026-08-27
- Revenue CAGR (3y)-91.0% SEC XBRL
- Beta0.54 as of 2026-08-27
- Last reported earnings2025-03-25 most recent in our data — SEC EDGAR Form 8-K (Item 2.02); no newer announcement filed
How GNLX compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-27
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-27
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-27
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How Genelux Corp looks technically
Genelux Corp (GNLX) is trading 15.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 139 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 48, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive). It made a new 20-day low about 16 trading days ago. It is 68.0% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 15.3% below its 200-day average, the long-term trend line — a long-term downtrend | -15.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.85 | $2.85 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.22 | $3.22 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 35 calendar days ago — the swings before that are what the structure reading is measured on | 35 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 3.005. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 139 trading days ago — a "death cross", a bearish long-term signal | 139 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with sellers in control | 29.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 48, neither overbought (above 70) nor oversold (below 30) | 48.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($2.52 to $2.82) — its "stochastic" reading is 70 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 70.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $8.54 | $8.54 |
|---|---|---|
| From the 52-week high | it is 68.0% below its 52-week high (its highest price of the past year) | -68.0% |
| Above the 52-week low | it is 19.2% above its 52-week low (its lowest price of the past year) | +19.2% |
| Below the 52-week high | it is 68.0% below its highest point of the past year | 68.0% |
| Since a 20-day breakout | it made a new 20-day low about 16 trading days ago | 16 sessions |
| Since a 55-day breakout | it made a new 55-day low about 16 trading days ago | 16 sessions |
| All-time high | its highest closing price on record is $40.98 (set on 2023-06-22) | $40.98 |
| Given back of the 52-week move | over the past year its closes ranged ($2.30 to $8.24), and it has recovered only a small part of its fall from last year’s high — 7% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.97 to $6.16. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 7.2% |
| From the all-time high | it is 93.3% below its all-time high | -93.3% |
| Nearest price level | it is trading 1.6% below a resistance level at $2.77 — a price it turned at 7 times since 2025-01-07, most recently on 2026-07-20. Since 2024-08-26 it has 2 such levels below the current price and 12 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.6% |
| All-time low | its lowest closing price on record is $1.60 (set on 2024-08-05) | $1.60 |
| Above the all-time low | it is 70.6% above its all-time low | +70.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 48th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1742 between its high and its low — about 6.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1742 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.49 and $2.98 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.49 – $2.74 – $2.98 |
| Typical daily range (% of price) | its price moves about 6.4% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.4% |
| Stretch from the 200-day average | it is trading 2.8 daily ranges below its 200-day average price (15.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.95× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bearish engulfing | 3 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 3 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-26 0.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.4% |
|---|---|---|
| Gap filled | a 2.1% gap up opened on 2026-07-30 has been "filled" 19 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 19 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 9.2 percentage points (the stock lost 5.5% while the market gained 3.7%) | -9.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 11.4 percentage points (the stock lost 9.3% while the market gained 2.1%) | -11.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 16.7 percentage points (the stock lost 5.5% while the market gained 11.1%) | -16.7% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 46.7 percentage points (the stock lost 28.0% while the market gained 18.7%) | -46.7% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 6.4% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-21 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 0.9% of the share price, which is taken to mean a barrier that gives way easily. | -6.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 2% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $2.77 — a volume-weighted average of daily closes over 160 sessions, not a true tick-by-tick VWAP. | -1.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% above the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $2.70 — a volume-weighted average of daily closes over 10 sessions, not a true tick-by-tick VWAP. | +1.2% |
Price levels it has turned at before
GNLX last closed at $2.73 on 2026-08-26. Since 2024-08-26 it has turned at 2 prices below its last close and 12 above; the 2 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.77 | Resistance | 1.6% above the last close | turned there 7 times · 2025-01-07 to 2026-07-20 |
| $2.90 | Resistance | 6.4% above the last close | turned there twice · 2026-03-10 to 2026-04-09 |
| $3.02 | Resistance | 10.4% above the last close | turned there four times · 2025-07-16 to 2026-07-22 |
| $2.31 | Support | 15.3% below the last close | turned there six times · 2024-11-15 to 2026-04-09 |
| $2.25 | Support | 17.5% below the last close | turned there twice · 2025-01-15 to 2025-05-07 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $3.00.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-26.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · lagging the market · Printed a doji candle · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-26. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.17 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$17.50 range $10.00 – $31.00; median $16.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for GNLX
- Consensus EPS estimate-$0.2 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Lead product Olvi-Vec is in late-stage clinical development with no approved products yet; regulatory approval is uncertain and clinical trial failure would be existential.","Company is currently pre-revenue with substantial operating losses ($9.2M in Q1 2026) and a net margin of -115,588%, making it dependent on equity financing and extremely cash-constrained.","Oncolytic virus therapies are novel and represent significant technical and manufacturing complexity; manufacturing scale-up and cGMP compliance risks could delay commercialization or increase costs."]
What changed in the latest 10-Q
AI-assisted comparison of GNLX's 10-Q filed 2026-05-07 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-07) adds section 'Data from Lung Cancer Clinical Trials' with detailed interim results from two ongoing trials announced January 5, 2026
- Newer filing adds specific clinical trial data for Ph1b/2 SCLC trial (NCT07136285) conducted by Newsoara in China, including 9 evaluable patients, 33% ORR, 67% DCR, and exploratory durability signals
- Newer filing adds data for Phase 2 VIRO-25 trial (NCT06463665) evaluating Olvi-Vec in advanced or metastatic recurrent NSCLC
- Newer filing mentions January 2026 underwritten offering of 6,666,667 shares at $3.00 per share with $18.5 million net proceeds
- Newer filing states stockholders' equity of $22.9 million at March 31, 2026 and cash position of $26.3 million expected to last into first quarter of 2027
- Newer filing refers to financial year ended December 31, 2025 in opening paragraph
- Removed:
- Older filing (2025-11-05) references refer to nine months ended September 30, 2025 with net losses of $22.9 million and $20.9 million; newer filing references three months ended March 31, 2026 with net losses of $8.9 million and $7.5 million
- Older filing states accumulated deficit of $274.3 million at September 30, 2025; newer filing states $292.5 million at March 31, 2026
- Older filing describes history of IPO in 2023, second public offering in 2024, and third offering in March 2025 with specific proceeds amounts
- Older filing mentions stockholders' equity of $18.6 million at September 30, 2025 and cash position of $21.0 million expected to last into third quarter of 2026
- Older filing contains detailed 'Officer Transition' subsection regarding Eric Groen appointment on July 7, 2025
- Older filing contains 'Results of Operations' section with subsections on Net Sales and Operating Expenses
- Reworded:
- Older filing states company is 'focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types'; newer filing removes 'pipeline of' and 'solid' qualifiers
- Older filing refers to 'Our product candidate, Olvi-Vec'; newer filing changes to 'Our lead product candidate, Olvi-Vec'
- Older filing uses 'need substantial additional funding'; newer filing uses 'require substantial additional funding'
- Older filing states 'Until we can generate significant revenue'; newer filing states 'Until we generate significant revenue'
- Older filing lists funding sources as 'public or private equity offerings and debt financings, which may include sales of shares of Company common stock under the Sales Agreement entered into with Guggenheim Securities, LLC in February 2024 (ATM Sales), or other sources'; newer filing lists 'public or private equity offerings, debt and/or other sources, such as milestone payments, royalties or other payments or funding from existing or potential collaboration agreements'
- Notes:
- Newer filing text appears truncated at end of VIRO-25 trial section ('The t')
- Older filing contains a 'Results of Operations' section that is not fully reproduced in the provided excerpt, limiting assessment of completeness of removals
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 6 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 3 sells ($12752) — 3 selling insiders
- Last 90 days0 buys · 6 sells ($78014) — 6 selling insiders
- Last 180 days0 buys · 10 sells ($90642) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-04. As of 2026-08-27.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about GNLX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding GNLX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 564,825
- Reported value $1,366,876
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 1 increased, 1 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
GNLX had 3,083,334 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
GNLX had 6.81% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 20.15 days to cover at the same settlement.
- Reported short interest (shares) 3,083,334
- Short interest (% of shares outstanding) 6.81%
- Prior settlement (shares) 3,113,408
- Reported change -0.97%
- Days to cover (reported) 20.15
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Replimune (REPL)
- Turnstone Biologics
- SillaJen
- Western Oncolytics
- Targovax
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare GNLX vs…
Frequently asked questions
What does Genelux Corp (GNLX) do?
Genelux is a late clinical-stage biopharmaceutical company focused on developing oncolytic viral immunotherapies for aggressive and difficult-to-treat cancers. The company's lead candidate, Olvi-Vec, is a proprietary modified vaccinia virus designed to selectively kill tumor cells and induce patient-specific immune responses against tumor neoantigens.
What sector is Genelux Corp (GNLX) in?
Genelux Corp (GNLX) is classified in the Health Care sector. Its industry is Oncolytic viral immunotherapy / biopharmaceutical. It trades on NASDAQ.
Who are Genelux Corp's (GNLX) competitors?
Notable peers of Genelux Corp (GNLX) include Replimune, Turnstone Biologics, SillaJen, Western Oncolytics and Targovax. This peer set is informational only — not financial advice.
Is Genelux Corp (GNLX) overbought or oversold right now?
Genelux Corp (GNLX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 48, in the neutral middle (as of 2026-08-26). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on GNLX come from?
Fundamentals and prices come from market data, as of 2026-08-27; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-27. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-26.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.